Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images

BACKGROUND: Currently, only a fraction of patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) experience a durable clinical benefit (DCB). According to NCCN guidelines, Programmed death-ligand 1 (PD-L1) expression status determined by immunohistochemistr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunother Cancer
Auteurs principaux: Mu, Wei, Jiang, Lei, Shi, Yu, Tunali, Ilke, Gray, Jhanelle E, Katsoulakis, Evangelia, Tian, Jie, Gillies, Robert J, Schabath, Matthew B
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2021
Sujets:
Immunotherapy Biomarkers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8211060/
https://ncbi.nlm.nih.gov/pubmed/34135101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002118
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires